-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network August 23 News On August 18, Sichuan Huiyu Pharmaceutical submitted a clinical application for butylphthalide injection 2.
2 as a new drug, and was contracted by CDE
.
At present, the only butylphthalide-related products on the domestic market are CSPC's butylphthalide sodium chloride injection and butylphthalide soft capsules, which are used to improve neurological deficits in patients with acute ischemic stroke
.
2 as a new drug, and was contracted by CDE
.
At present, the only butylphthalide-related products on the domestic market are CSPC's butylphthalide sodium chloride injection and butylphthalide soft capsules, which are used to improve neurological deficits in patients with acute ischemic stroke
.
Figure 1: Product information of the newly declared clinical product
Source: CDE official website
Figure 2: Sales of Butylphthalide (Unit: Ten Thousand Yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2020, in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions), the sales of butylphthalide will exceed 6 billion yuan in 2020, including injections.
Maintain a rapid growth trend
.
com, in 2020, in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions), the sales of butylphthalide will exceed 6 billion yuan in 2020, including injections.
Maintain a rapid growth trend
.
Table 1: Application status of butylphthalide injection products
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, in addition to Huiyu’s clinical application of new drugs, Livzon has already submitted an application for the generic listing of 4 types of butylphthalide sodium chloride injection and has been approved for clinical use.
The BE trial is currently underway; and Nanjing Youke Pharmaceutical|Nanjing Libowei In 2020, the pharmaceutical company submitted a new drug application for butylphthalide injection 2.
2 and is under review.
The time advantage is obvious
.
The BE trial is currently underway; and Nanjing Youke Pharmaceutical|Nanjing Libowei In 2020, the pharmaceutical company submitted a new drug application for butylphthalide injection 2.
2 and is under review.
The time advantage is obvious
.
Table 2: Situation of injection products declared by Huiyu
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Huiyu Pharmaceuticals has gained a lot in the field of injections in recent years.
At present, there are 7 products that have been approved and reviewed.
All of them have won the national centralized procurement except for irinotecan hydrochloride injection.
The 7 injections under review are also in accordance with The new classification is applied for listing, and approval is regarded as over-evaluation; the butylphthalide injection applied for clinical application is the first new drug submitted by the company, and Huiyu's research and development results on high-end injections are entering the harvest period
.
At present, there are 7 products that have been approved and reviewed.
All of them have won the national centralized procurement except for irinotecan hydrochloride injection.
The 7 injections under review are also in accordance with The new classification is applied for listing, and approval is regarded as over-evaluation; the butylphthalide injection applied for clinical application is the first new drug submitted by the company, and Huiyu's research and development results on high-end injections are entering the harvest period
.
Source: CDE official website, Minet database
The review data statistics are as of August 20, if there are any errors or omissions, please correct me
.
.
Medical Network August 23 News On August 18, Sichuan Huiyu Pharmaceutical submitted a clinical application for butylphthalide injection 2.
2 as a new drug, and was contracted by CDE
.
At present, the only butylphthalide-related products on the domestic market are CSPC's butylphthalide sodium chloride injection and butylphthalide soft capsules, which are used to improve neurological deficits in patients with acute ischemic stroke
.
2 as a new drug, and was contracted by CDE
.
At present, the only butylphthalide-related products on the domestic market are CSPC's butylphthalide sodium chloride injection and butylphthalide soft capsules, which are used to improve neurological deficits in patients with acute ischemic stroke
.
Figure 1: Product information of the newly declared clinical product
Source: CDE official website
Figure 2: Sales of Butylphthalide (Unit: Ten Thousand Yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2020, in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions), the sales of butylphthalide will exceed 6 billion yuan in 2020, including injections.
Maintain a rapid growth trend
.
com, in 2020, in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions), the sales of butylphthalide will exceed 6 billion yuan in 2020, including injections.
Maintain a rapid growth trend
.
Table 1: Application status of butylphthalide injection products
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, in addition to Huiyu’s clinical application of new drugs, Livzon has already submitted an application for the generic listing of 4 types of butylphthalide sodium chloride injection and has been approved for clinical use.
The BE trial is currently underway; and Nanjing Youke Pharmaceutical|Nanjing Libowei In 2020, the pharmaceutical company submitted a new drug application for butylphthalide injection 2.
2 and is under review.
The time advantage is obvious
.
The BE trial is currently underway; and Nanjing Youke Pharmaceutical|Nanjing Libowei In 2020, the pharmaceutical company submitted a new drug application for butylphthalide injection 2.
2 and is under review.
The time advantage is obvious
.
Table 2: Situation of injection products declared by Huiyu
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Huiyu Pharmaceuticals has gained a lot in the field of injections in recent years.
At present, there are 7 products that have been approved and reviewed.
All of them have won the national centralized procurement except for irinotecan hydrochloride injection.
The 7 injections under review are also in accordance with The new classification is applied for listing, and approval is regarded as over-evaluation; the butylphthalide injection applied for clinical application is the first new drug submitted by the company, and Huiyu's research and development results on high-end injections are entering the harvest period
.
At present, there are 7 products that have been approved and reviewed.
All of them have won the national centralized procurement except for irinotecan hydrochloride injection.
The 7 injections under review are also in accordance with The new classification is applied for listing, and approval is regarded as over-evaluation; the butylphthalide injection applied for clinical application is the first new drug submitted by the company, and Huiyu's research and development results on high-end injections are entering the harvest period
.
Source: CDE official website, Minet database
The review data statistics are as of August 20, if there are any errors or omissions, please correct me
.
.
Medical Network August 23 News On August 18, Sichuan Huiyu Pharmaceutical submitted a clinical application for butylphthalide injection 2.
2 as a new drug, and was contracted by CDE
.
At present, the only butylphthalide-related products on the domestic market are CSPC's butylphthalide sodium chloride injection and butylphthalide soft capsules, which are used to improve neurological deficits in patients with acute ischemic stroke
.
2 as a new drug, and was contracted by CDE
.
At present, the only butylphthalide-related products on the domestic market are CSPC's butylphthalide sodium chloride injection and butylphthalide soft capsules, which are used to improve neurological deficits in patients with acute ischemic stroke
.
Figure 1: Product information of the newly declared clinical product
Source: CDE official website
Figure 2: Sales of Butylphthalide (Unit: Ten Thousand Yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2020, in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions), the sales of butylphthalide will exceed 6 billion yuan in 2020, including injections.
Maintain a rapid growth trend
.
Hospital hospital hospitalcom, in 2020, in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions), the sales of butylphthalide will exceed 6 billion yuan in 2020, including injections.
Maintain a rapid growth trend
.
Table 1: Application status of butylphthalide injection products
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, in addition to Huiyu’s clinical application of new drugs, Livzon has already submitted an application for the generic listing of 4 types of butylphthalide sodium chloride injection and has been approved for clinical use.
The BE trial is currently underway; and Nanjing Youke Pharmaceutical|Nanjing Libowei In 2020, the pharmaceutical company submitted a new drug application for butylphthalide injection 2.
2 and is under review.
The time advantage is obvious
.
The BE trial is currently underway; and Nanjing Youke Pharmaceutical|Nanjing Libowei In 2020, the pharmaceutical company submitted a new drug application for butylphthalide injection 2.
2 and is under review.
The time advantage is obvious
.
Table 2: Situation of injection products declared by Huiyu
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Huiyu Pharmaceuticals has gained a lot in the field of injections in recent years.
At present, there are 7 products that have been approved and reviewed.
All of them have won the national centralized procurement except for irinotecan hydrochloride injection.
The 7 injections under review are also in accordance with The new classification is applied for listing, and approval is regarded as over-evaluation; the butylphthalide injection applied for clinical application is the first new drug submitted by the company, and Huiyu's research and development results on high-end injections are entering the harvest period
.
At present, there are 7 products that have been approved and reviewed.
All of them have won the national centralized procurement except for irinotecan hydrochloride injection.
The 7 injections under review are also in accordance with The new classification is applied for listing, and approval is regarded as over-evaluation; the butylphthalide injection applied for clinical application is the first new drug submitted by the company, and Huiyu's research and development results on high-end injections are entering the harvest period
.
Source: CDE official website, Minet database
The review data statistics are as of August 20, if there are any errors or omissions, please correct me
.
.
